Advanced earns SAR 153M in H1 2025; Q2 profit at SAR 82M 6 M 2025 Advanced turns to SAR 72M profit in Q1 2025 3 M 2025 Advanced turns to SAR 259.2M loss in 2024; Q4 at SAR 288M 12 M 2024 Advanced ...
The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease. Blenrep (belantamab mafodotin) has been approved in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback